FDA Grants Accelerated Approval to Umbralisib for Two Indications

On February 5, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to umbralisib for the following indications:

  • Adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen
  • Adult patients with relapsed or refractory follicular lymphoma who have received at least three prior lines of systemic therapy.

Read the FDA announcement.

Read TG Therapeutics' announcement.

Posted 2/8/2021

Upcoming Events

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington